Psoriasis

Panelists discuss how IL-17 inhibitors are generally well-tolerated, but common adverse effects include infections, particularly candidiasis, and potential increased suicidal ideation risk. Patients should be informed of candidiasis risk, especially with bimekizumab (Gordon, 2022), and monitored for mood changes, as IL-17s and IL-23s may impact mental health (Blauvelt, 2023). Open discussions help assess risks while ensuring treatment benefits.

Panelists discuss how IL-17 inhibitors are considered for plaque psoriasis based on disease severity, comorbidities, and patient preference. Selection factors include efficacy, safety, access, and cost. Clinical trial data guide choices, but real-world factors impact use. Dosing varies: secukinumab (300 mg weekly for 5 weeks, then monthly), ixekizumab (160 mg at week 0, then 80 mg biweekly for 12 weeks, then monthly), brodalumab (210 mg weekly for 3 weeks, then biweekly), and bimekizumab (320 mg every 4 weeks for 16 weeks, then every 8 weeks). Dosing and device options influence prescribing decisions.

Unlike biologics, nonbiologic systemic therapies showed a neutral or slightly increased cardiovascular risk, raising concerns about their long-term safety.

Positive changes in DLQI scores were observed after 4 weeks of therapy as well as the 6-month follow-up.

Bio-naïve patients and those without comorbidities had the highest treatment success rates with guselkumab.

PASI and DLQI scores are closely linked, but stigma and residual effects may still impact patient QoL.

Panelists discuss how inhibition of IL-17 in psoriasis treatment significantly improves quality of life by reducing inflammation, skin lesions, itching, and pain. Patients report better psychological well-being, increased social confidence, and improved daily functioning as inflammatory pathways are interrupted.

Panelists discuss how IL-17 inhibitors are biologics that target the inflammatory cytokine IL-17 pathway. They demonstrate rapid onset of action, with measurable improvement in most patients within 2 to 4 weeks and peak efficacy by 12 to 16 weeks. They achieve high rates of skin clearance in psoriasis patients and maintain efficacy with long-term use.

Treatment with tildrakizumab was still safe and effective after 1 year with notable improvements in patients’ quality of life.

A study reveals that biologics targeting IL-12, IL-23, and IL-17 lower the risk of serious infections in older adults with psoriatic disease.

At the 2025 AAD Annual Meeting, Alumis Inc. presented promising phase 2 STRIDE trial results for ESK-001, a TYK2 inhibitor showing sustained psoriasis improvements over 52 weeks.

Panelists discuss how IL-17 inhibitors differ in their targets within the IL-17 pathway. Secukinumab and ixekizumab block IL-17A, reducing inflammation in psoriasis and arthritis. Brodalumab inhibits IL-17RA, affecting multiple IL-17 cytokines, but carries suicide risk warnings. Bimekizumab targets IL-17A and IL-17F, potentially enhancing efficacy but with added risk of infections. These differences impact efficacy, safety, and patient selection in inflammatory diseases.

Panelists discuss how IL-17 is a key pro-inflammatory cytokine in plaque psoriasis pathogenesis. It stimulates keratinocyte proliferation, promotes neutrophil recruitment, induces antimicrobial peptides, and up-regulates other inflammatory mediators, creating a self-perpetuating inflammatory cascade in lesional skin.

Nail psoriasis affects 50% of plaque psoriasis patients, making effective treatments crucial.

This real-world data explores the use of the IL-17A blocker for up to 3 years in several subtypes of psoriasis.

The investigational drug, designed using AI technology, optimizes pharmacologic characteristics for psoriasis treatment.

The LITE study found home-based narrowband UV-B phototherapy is as effective as office-based treatment for psoriasis, with higher adherence and lower costs.

99% of posts on the platform were of poor quality, according to the DISCERN instrument.

By leveraging the innovative biomarker panels, clinicians can now offer more personalized and effective treatment options for psoriasis and AD.

Bissonnette shared highlights and insights on the icotrokinra data presented at the AAD Annual Meeting.

New results from Alumis show a positive clinical response and safety profile after 52 weeks of treatment for patients with plaque psoriasis.

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

According to a poster from AAD, the National Psoriasis Foundation’s treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.

Findings suggest that most patients on risankizumab met or exceeded the National Psoriasis Foundation’s treatment goals.